New findings by researchers at Sylvester Comprehensive Cancer Center may prove to be an important solution to one of the more difficult problems faced in the field of precision medicine when it comes to treating cancer. An article reporting their findings, “Discordancy Partitioning for Validating Potentially Inconsistent Pharmacogenomic Studies,” was published online November 9 by Scientific Reports.
Sylvester Researchers and Colleagues Identify Novel Therapeutic Target for Incurable Prostate Cancer
A collaborative study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues has identified a novel therapeutic target for incurable prostate cancer. The research found a critical role for thioredoxin-1, a protein that protects cells from oxidative stress, in the progression of prostate cancer to the incurable castration-resistant stage.
An international collaboration among researchers in Miami, New York, and Montreal aims to determine the best strategies for effectively providing people who inject drugs with pre-exposure prophylaxis (PrEP) to protect them from HIV infection. Their efforts will be backed by an $8 million grant just awarded from the National Institute on Drug Abuse.
More and more often in this era of big data, it’s not a lack of information that’s the issue. Instead, it can be sorting through a tsunami of data to find what’s most relevant and meaningful to drive medical research forward. Now a $1.4 million grant from the National Institute of Health will boost efforts of a team of researchers at the University of Miami Miller School of Medicine.